Braveheart Bio, Inc.

BRVE

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

19.62 0.88 −4.29%
Market cap
$1.8B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−28.7%
Net debt / EBITDA
1.3×
Payout ratio
—
Dec '25
Current Ratio
17.03
Net Debt/EBITDA
1.34
Debt/Equity
0.00
ROE
0.00%
ROA
0.00%
ROIC
0.00%
Return on Tangible Assets
(78.60%)
Free Cash Flow per Share
(0.52)
Book value per Share
(17.15)
Free Cash Flow
(2.01)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 12 Nov 2026